Compare Gilead Sciences, Inc. (GILD) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Snowflake Inc — how do they compare? Gilead Sciences, Inc. trades at $133.51 (market cap $163.51B), while Snowflake Inc trades at $273.09 (market cap $94.23B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Snowflake Inc pays none. Which is the better fit depends on your goals.
| GILD | SNOW | |
|---|---|---|
Market Cap | $163.51B | $94.23B |
Sector | Health | Technology |
52-Week High | $155.80 | $280.16 |
52-Week Low | $108.22 | $121.11 |
Enterprise Value | $178.05B | $94.05B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Snowflake (SNOW) trades at $273.26, down 0.97% on the day, with strong technical momentum showing a bullish moving average signal. The company continues to deliver impressive revenue growth, reaching $3.63 billion in 2025, while maintaining consistent earnings beats in recent quarters. Analyst sentiment remains overwhelmingly positive with 80.77% buy ratings and a $297.35 consensus price target, representing 8.8% upside potential from current levels.
Despite strong growth fundamentals, Snowflake faces significant profitability challenges with a -23.79% net margin and negative ROE of -55.07%. The stock trades at premium valuations (P/S 18.4x, P/B 48.6x) while burning cash, creating execution risk. However, accelerating AI Data Cloud adoption and CEO's ambitious $184 billion market cap target by 2033 provide long-term growth catalysts if the company can achieve sustainable profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
